Related references
Note: Only part of the references are listed.Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Ronan T. Swords et al.
BLOOD (2018)
Getting to transplant in Hodgkin lymphoma: BVB
Leo I. Gordon
BLOOD (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Jorge Cortes et al.
LANCET ONCOLOGY (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux et al.
LEUKEMIA (2018)
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Michael Seiler et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
Martin Wermke et al.
LANCET HAEMATOLOGY (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Good news for patients with myelodysplastic syndromes and thrombocytopenia
Moshe Mittelman
LANCET HAEMATOLOGY (2018)
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
Anne Sophie Kubasch et al.
CANCERS (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia
Anne Sophie Kubasch et al.
BLOOD ADVANCES (2018)
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball et al.
BLOOD ADVANCES (2018)
Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive
David P. Steensma et al.
BLOOD (2018)
Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study
Emanuele Angelucci et al.
BLOOD (2018)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
M. Robin et al.
BONE MARROW TRANSPLANTATION (2017)
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes
Chun-Kang Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Christian Scharenberg et al.
HAEMATOLOGICA (2017)
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Christian Scharenberg et al.
HAEMATOLOGICA (2017)
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Sophie Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kroeger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Uwe Platzbecker et al.
LANCET ONCOLOGY (2017)
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
U. Platzbecker et al.
LEUKEMIA (2017)
Decitabine in TP53-Mutated AML
Guillermo Montalban-Bravo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-beta superfamily inhibitors
Anna Mies et al.
SEMINARS IN HEMATOLOGY (2017)
CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Claudia Brunetti et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
Hee Sue Park et al.
ANNALS OF LABORATORY MEDICINE (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Charles F. Craddock et al.
CLINICAL CANCER RESEARCH (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems
Rena Buckstein et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
M. T. Voso et al.
ANNALS OF ONCOLOGY (2017)
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati et al.
BLOOD (2017)
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study
Ali T. Taher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo de Witte et al.
BLOOD (2017)
Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CANCER (2017)
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
D. A. Sallman et al.
LEUKEMIA (2016)
Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
U. Oelschlaegell et al.
LEUKEMIA (2016)
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
A. Toma et al.
LEUKEMIA (2016)
Time-dependent changes in mortality and transformation risk in MDS
Michael Pfeilstoecker et al.
BLOOD (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
M. Mossner et al.
LEUKEMIA (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
Unraveling the Pathogenesis of MDS: The NLRP3 inflammasome and Pyroptosis Drive the MDS Phenotype
David A. Sallman et al.
FRONTIERS IN ONCOLOGY (2016)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia
Manja Meggendorfer et al.
HAEMATOLOGICA (2015)
HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
M. Robin et al.
LEUKEMIA (2015)
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia
Manja Meggendorfer et al.
HAEMATOLOGICA (2015)
Myelodysplasia is in the niche: novel concepts and emerging therapies
E. Bulycheva et al.
LEUKEMIA (2015)
Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis
Philippe Armand et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
Aristoteles Giagounidis et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
U. Platzbecker et al.
LEUKEMIA (2014)
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
M. Tobiasson et al.
BLOOD CANCER JOURNAL (2014)
Allogeneic stem cell transplantation in MDS: How? When?
Uwe Platzbecker et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2013)
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Valeria Santini et al.
BLOOD (2013)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
Yun-Gyoo Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
U. Platzbecker et al.
LEUKEMIA (2013)
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
C. Kelaidi et al.
LEUKEMIA (2013)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
Arjan A. van de Loosdrecht et al.
LEUKEMIA & LYMPHOMA (2013)
Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
Uwe Platzbecker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen
Christian Saure et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
H. Joachim Deeg et al.
BLOOD (2012)
MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation
Martin Wermke et al.
CLINICAL CANCER RESEARCH (2012)
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
Gandhi Damaj et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide
A. A. N. Giagounidis et al.
LEUKEMIA (2012)
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
Uwe Platzbecker et al.
LEUKEMIA RESEARCH (2012)
Immunomodulatory Treatment of Myelodysplastic Syndromes: Antithymocyte Globulin, Cyclosporine, and Alemtuzumab
Ankur R. Parikh et al.
SEMINARS IN HEMATOLOGY (2012)
Iron overload in MDS-pathophysiology, diagnosis, and complications
Norbert Gattermann et al.
ANNALS OF HEMATOLOGY (2011)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
Elaine M. Sloand et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)
Uwe Platzbecker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
Mohamed L. Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Share Paper
